Product Details
| Alternate Name | Vascular endothelial growth factor A, VEGF-A, Vascular permeability factor, VPF, VEGF, MGC70609. |
|---|---|
| Gene Symbol | VEGFA |
| Gene ID | 7422 |
| Accession # | P15692 |
| Source | E. coli |
| Appearance | Lyophilized protein |
| Physical Form Description | Lyophilized with no additives |
| Molecular Weight | 28.4 kDa |
| Purity by SDS-PAGE | ≥98% |
| Purity by | ≥98% |
| Endotoxin Level | <0.1 ng/μg |
| Biological Activity | Determined by the dose-dependent stimulation of the proliferation of human μmbilical vein endothelial cells (HUVEC) using a concentration range of 0.1-0.5 ng/ml. |
| Reconstitution Instructions | Reconstitute in H₂O to a concentration of 0.1-1.0 mg/ml. This solution can then be diluted into other aqueous buffers and stored at 4°C for 1 week or –20°C for future use. |
| Handling | Centrifuge the vial prior to opening. |
| Storage Conditions | -20°C |
| Shipping Conditions | Gel Pack |
| USAGE | For Research Use Only! Not to be used in humans |
Details
VEGF (Vascular Endothelial Growth Factor) is a secreted homodimeric protein, secreted by a variety of Vascularized tissues. VEGF stimulates endothelial cell growth, angiogenesis, and capillary permeability. Human VEGF is a 28.4 kDa homodimeric protein consisting of two 121 amino acid polypeptide chains.
Why buy BioVision Products?
 |
 |
 |
 |
Innovation |
Affordability |
Global Presence |
Technical Support |
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways. |
BioVision is committed to providing the highest quality products at a competitive price. |
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery. |
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently. |
Caballero, S. et. al. Selective Blockade of Cytoskeletal Actin Remodeling Reduces Experimental Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci., Apr 2011; 52: 2490 - 2496.
For more citations of this product click here
